Quick Answer
OptimizeRx Corp reported Long-Term Debt of $21.42 million for fiscal year 2025.
OptimizeRx Corp Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $21.42M | -30.5% |
| 2024 | $30.82M | -10.0% |
| 2023 | $34.23M | — |
| 2011 | $0.00 | -100.0% |
| 2010 | $1.00M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.80M | -25.5% | -1.3% |
| June 30, 2025 | $25.13M | -22.2% | -13.9% |
| March 31, 2025 | $29.19M | -9.9% | -5.3% |
| December 31, 2024 | $30.82M | -10.0% | -7.4% |
| September 30, 2024 | $33.28M | — | +3.0% |
| June 30, 2024 | $32.30M | — | -0.4% |
| March 31, 2024 | $32.41M | — | -5.3% |
| December 31, 2023 | $34.23M | — | — |
- OptimizeRx Corp showed a decrease of -30.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2010–2025 period, OptimizeRx Corp’s long-term debt has grown by 2042.1% (from $1.00 million to $21.42 million).
- The most recent figure is from OptimizeRx Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: